SightGlass Vision, DOT Lenses and the Myopia Management Opportunity Independents Are Missing

More than 1.5 million children worldwide have already worn SightGlass Vision's DOT spectacle lenses. Now the company wants every eye care professional to understand why contrast management — not just lens design — is the mechanism at the centre of modern myopia control.

SightGlass Vision launched its global professional education campaign, Control the Contrast, in April 2026. The campaign targets eye care professionals directly, building awareness of the science underpinning its DOT (Diffusion Optics Technology) spectacle lenses and their role in slowing myopia progression in children.

The timing is deliberate. Childhood myopia is accelerating. Children spending increasing amounts of time indoors — studying, reading, on screens — are exposed to artificial visual environments that clinical evidence links to faster axial elongation. SightGlass has built its campaign around that environmental argument.

What DOT lenses actually do

DOT lenses work by integrating thousands of microscopic light-scattering elements across the lens surface. These elements soften the contrast reaching the retina, mimicking more natural visual conditions — the kind of conditions associated with outdoor environments rather than the high-contrast indoor settings children now spend most of their day in.

The hypothesis: when the retina consistently detects high-contrast visual signals, it triggers axial elongation. Reduce that contrast signal, and you slow the progression. The clinical data support it.

Twelve-month data from SightGlass clinical trials showed reductions in myopia progression of up to 75% versus control groups across diverse patient populations. At ARVO 2026 in May, the company presented 24-month data from the CATHAY trial, a long-term study in Chinese children aged 6 to 10. Those results showed DOT lenses saved more than 1.00 dioptres of progression on average over two years in that younger age group. Across the full study population aged six to thirteen, the lenses slowed average myopia progression by 0.78D — a 67% reduction — and slowed axial length progression by 0.40mm — a 62% reduction versus control.

The figure that translates most cleanly into a patient conversation: 59% of DOT lens wearers had myopia progression of 0.50D or less after 2 years. In the control group, that figure was 19%. That difference is statistically significant, and it is the kind of number a parent understands without a clinical dictionary.

Also presented at ARVO 2026: children wearing DOT lenses showed viewing behaviour similar to that with standard single-vision lenses across a range of daily activities. For any parent wondering whether the lenses feel or work differently day to day, the answer from the data is no.

A separate study presented at the 2026 Netherlands Contact Lens Congress found no significant increase in refractive astigmatism in children wearing DOT lenses — an important safety signal for practitioners considering long-term prescribing. DOT lenses are now available in the UK, alongside China, Canada, Israel and Spain. SightGlass Vision operates as a joint venture of CooperVision and Essilor International.

A campaign, not just a product launch

Control the Contrast is framed as education rather than promotion. SightGlass has built a dedicated resource hub for practitioners, covering the science behind contrast management, how different visual environments affect eye growth rates, and downloadable lens materials for use in practice.

Andrew Sedgwick, CEO of SightGlass Vision, put it plainly: more children are developing myopia at younger ages, and early intervention depends on practitioners being aware of all available options. The campaign exists to close that knowledge gap.

That gap is real. Myopia management as a clinical discipline has grown substantially over the last decade, but awareness of contrast management — as distinct from peripheral defocus or orthokeratology — remains uneven across the profession.

What this means for an independent practice

Myopia management is not a one-appointment service. It is a years-long clinical relationship built around six-monthly reviews, progression monitoring, lens supply, parent education and, increasingly, sibling and family referrals. That structure suits independent practice in a way that it will never suit a corporate multiple operating on standardised appointment slots and staff turnover.

An independent practice that positions itself as the local authority on myopia management — across spectacle lenses, contact lenses and the growing body of clinical evidence — builds a patient retention model that compounds. Children become adult patients. Parents refer. The practice becomes associated with expertise, not just eyewear.

DOT lenses are a spectacle-based option. That matters. Not every family will accept contact lenses for a six-year-old. Not every child is a suitable candidate for orthokeratology. A practice that can offer a credible, evidence-based spectacle option as part of a broader myopia management offering can cover a broader clinical population — and keep more patients in-house rather than referring them elsewhere.

Corporations will stock myopia management products. They will not invest the time to make a practice genuinely known for myopia expertise in a local community. That positioning is available to independents. Most are not taking it yet.

How to get them in your practice

DOT lenses have been available for early access in the UK since September 2025, ordered directly from SightGlass Vision's UK entity. There is no intermediary. The UK and Ireland contact is Greg Cahill, Sales Project Manager, at greg.cahill@sightglassvision.com.

Two things worth knowing before you call. First, the lenses carry a two-year warranty against manufacturing defects. Second — and this is the one to lead with in a parent conversation — SightGlass Vision offers a progression guarantee: if a child's prescription changes by -0.50D or more in either eye within 12 months of purchase, both lenses are replaced free of charge in the updated prescription. For a parent weighing the cost of myopia management against standard single-vision lenses, that changes the conversation.

Dispensing is restricted to GOC-registered dispensing opticians and optometrists. Which is as it should be — this is a clinical service, not a retail product.

The clinical governance point

Myopia management services — regardless of which product modality — require appropriate clinical governance, accreditation and documentation frameworks. The CATHAY and CYPRESS trial data supporting DOT lenses are peer-reviewed and substantial, but the prescribing decision rests with the practitioner. Confirm your CPD and clinical protocols are in place before expanding into any new myopia management offering.

This is exactly the kind of service development our Grow Independent programme is built around. Book a Free 20-Minute Practice Growth Call